-DOCSTART- -X- O
Streptococcus -X- _ B-Patient
pneumoniae -X- _ I-Patient
is -X- _ O
the -X- _ O
most -X- _ O
important -X- _ O
pathogen -X- _ O
causing -X- _ O
community-acquired -X- _ O
pneumonia -X- _ O
( -X- _ O
CAP -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
current -X- _ O
diagnostic -X- _ O
microbial -X- _ O
standard -X- _ O
detects -X- _ O
S. -X- _ O
pneumoniae -X- _ O
in -X- _ O
less -X- _ O
than -X- _ O
30 -X- _ O
% -X- _ O
of -X- _ O
CAP -X- _ O
cases. -X- _ O
A -X- _ O
quantitative -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
( -X- _ O
PCR -X- _ O
) -X- _ O
targeting -X- _ O
autolysin -X- _ O
( -X- _ O
lytA -X- _ O
) -X- _ O
is -X- _ O
able -X- _ O
to -X- _ O
increase -X- _ O
the -X- _ O
rate -X- _ O
of -X- _ O
detection. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
is -X- _ O
validation -X- _ O
of -X- _ O
this -X- _ O
quantitative -X- _ B-Intervention
PCR -X- _ I-Intervention
in -X- _ O
vitro -X- _ O
using -X- _ O
different -X- _ O
available -X- _ O
strains -X- _ O
and -X- _ O
in -X- _ O
vivo -X- _ O
using -X- _ O
clinical -X- _ O
samples -X- _ O
( -X- _ O
oropharyngeal -X- _ B-Intervention
swabs -X- _ I-Intervention
) -X- _ O
. -X- _ O
The -X- _ O
PCR -X- _ O
autolysin -X- _ O
( -X- _ O
lytA -X- _ O
) -X- _ O
was -X- _ O
validated -X- _ O
by -X- _ O
testing -X- _ O
the -X- _ O
intra- -X- _ O
and -X- _ O
inter-run -X- _ O
variability. -X- _ O
Also -X- _ O
, -X- _ O
the -X- _ O
in -X- _ O
vitro -X- _ O
specificity -X- _ O
and -X- _ O
sensitivity -X- _ O
, -X- _ O
including -X- _ O
the -X- _ O
lower -X- _ O
limit -X- _ O
of -X- _ O
detection -X- _ O
was -X- _ O
determined. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
a -X- _ O
pilot-study -X- _ O
was -X- _ O
performed -X- _ O
using -X- _ O
samples -X- _ B-Patient
from -X- _ I-Patient
patients -X- _ I-Patient
( -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
28 -X- _ I-Patient
) -X- _ I-Patient
with -X- _ I-Patient
pneumococcal -X- _ I-Patient
pneumonia -X- _ I-Patient
and -X- _ O
patients -X- _ B-Comparison
( -X- _ I-Comparison
n -X- _ I-Comparison
= -X- _ I-Comparison
28 -X- _ I-Comparison
) -X- _ I-Comparison
with -X- _ I-Comparison
a -X- _ I-Comparison
pneumonia -X- _ I-Comparison
without -X- _ I-Comparison
detection -X- _ I-Comparison
of -X- _ I-Comparison
S. -X- _ I-Comparison
pneumoniae -X- _ I-Comparison
with -X- _ I-Comparison
the -X- _ I-Comparison
current -X- _ I-Comparison
diagnostic -X- _ I-Comparison
microbial -X- _ I-Comparison
standard -X- _ I-Comparison
, -X- _ O
but -X- _ O
with -X- _ O
detection -X- _ O
of -X- _ O
either -X- _ O
a -X- _ O
viral -X- _ O
and -X- _ O
or -X- _ O
another -X- _ O
bacterial -X- _ O
pathogen -X- _ O
to -X- _ O
validate -X- _ O
this -X- _ O
test -X- _ O
further. -X- _ O
The -X- _ B-Outcome
intra- -X- _ I-Outcome
and -X- _ I-Outcome
inter-run -X- _ I-Outcome
variability -X- _ I-Outcome
were -X- _ I-Outcome
relatively -X- _ I-Outcome
low -X- _ I-Outcome
( -X- _ I-Outcome
SD’s -X- _ I-Outcome
ranging -X- _ I-Outcome
from -X- _ I-Outcome
0.08 -X- _ I-Outcome
to -X- _ I-Outcome
0.96 -X- _ I-Outcome
cycle -X- _ I-Outcome
thresholds -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
lower -X- _ I-Outcome
limit -X- _ I-Outcome
of -X- _ I-Outcome
detection -X- _ I-Outcome
turned -X- _ I-Outcome
out -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
1–10 -X- _ I-Outcome
DNA -X- _ I-Outcome
copies -X- _ I-Outcome
/ -X- _ I-Outcome
reaction. -X- _ I-Outcome
In-vitro -X- _ I-Outcome
sensitivity -X- _ I-Outcome
and -X- _ I-Outcome
specificity -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
tested -X- _ I-Outcome
specimens -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
strains -X- _ I-Outcome
carrying -X- _ I-Outcome
lytA -X- _ I-Outcome
and -X- _ I-Outcome
6 -X- _ I-Outcome
strains -X- _ I-Outcome
negative -X- _ I-Outcome
for -X- _ I-Outcome
lytA -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
both -X- _ I-Outcome
100 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
pneumococcal -X- _ I-Outcome
and -X- _ I-Outcome
non- -X- _ I-Outcome
pneumococcal -X- _ I-Outcome
pneumonia -X- _ I-Outcome
a -X- _ I-Outcome
cut-off -X- _ I-Outcome
value -X- _ I-Outcome
of -X- _ I-Outcome
6.000 -X- _ I-Outcome
copies -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
would -X- _ I-Outcome
lead -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
sensitivity -X- _ I-Outcome
of -X- _ I-Outcome
57.1 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
specificity -X- _ I-Outcome
of -X- _ I-Outcome
85.7 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
We -X- _ I-Outcome
were -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
develop -X- _ I-Outcome
a -X- _ I-Outcome
quantitative -X- _ I-Outcome
PCR -X- _ I-Outcome
targeting -X- _ I-Outcome
lytA -X- _ I-Outcome
with -X- _ I-Outcome
good -X- _ I-Outcome
in-vitro -X- _ I-Outcome
test -X- _ I-Outcome
characteristics. -X- _ I-Outcome
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1007 -X- _ O
/ -X- _ O
s11033-018-4558-0 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

